...
首页> 外文期刊>International journal of clinical practice >Efficacy and tolerability studies evaluating a sleep aid and analgesic combination of naproxen sodium and diphenhydramine in the dental impaction pain model in subjects with induced transient insomnia
【24h】

Efficacy and tolerability studies evaluating a sleep aid and analgesic combination of naproxen sodium and diphenhydramine in the dental impaction pain model in subjects with induced transient insomnia

机译:评估萘普生钠和苯海拉明合用的睡眠辅助和止痛药在诱发短暂性失眠患者牙齿撞击疼痛模型中的功效和耐受性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Study Objectives: The aim of this study was to evaluate the efficacy and tolerability of novel combination naproxen sodium (NS) and diphenhydramine (DPH) in subjects with postoperative dental pain along with transient insomnia induced by 5 h sleep phase advance. The present studies aimed to demonstrate the added benefit and optimal dosages of the combination product over individual ingredients alone in improving sleep and pain. Methods: Each of the two studies was a two-centre, randomised, double-blind and double-dummy trial. In the first study, subjects were randomised into one of the following treatment arms: NS 440 mg/DPH 50 mg, NS 220 mg/DPH 50 mg, NS 440 mg or DPH 50 mg. In the second study, subjects received either NS 440 mg/DPH 25 mg, NS 440 mg or DPH 50 mg. The co-primary end-points in both studies were wake time after sleep onset (WASO) and sleep latency (SL) measured by actigraphy. Other secondary sleep and pain end-points were also assessed. Results: The intent-to-treat population included 712 and 267 subjects from studies one and two, respectively. In the first study, only the NS 440 mg/DPH 50 mg combination showed significant improvements in both WASO vs. NS alone (-70.3 min p = 0.0002) and SL vs. DPH alone (25.50 and 41.50 min respectively, p < 0.0001). In the second study, the NS 440 mg/DPH 25 mg combination failed to show any significant improvements vs. either component alone. Conclusions: Only the NS 440 mg/DPH 50 mg combination demonstrated improvement in both sleep latency vs. DPH 50 mg and sleep maintenance (WASO) vs. NS 440 mg. There were no serious or unexpected adverse events reported in either study.
机译:研究目的:这项研究的目的是评估新型萘普生钠(NS)和苯海拉明(DPH)联合治疗对5小时睡眠阶段导致的术后牙痛以及短暂性失眠的患者的疗效和耐受性。本研究旨在证明与单独使用单独成分相比,组合产品在改善睡眠和疼痛方面具有额外的益处和最佳剂量。方法:两项研究均为两项中心,随机,双盲和双模拟试验。在第一个研究中,将受试者随机分为以下治疗组之一:NS 440 mg / DPH 50 mg,NS 220 mg / DPH 50 mg,NS 440 mg或DPH 50 mg。在第二项研究中,受试者接受NS 440 mg / DPH 25 mg,NS 440 mg或DPH 50 mg。两项研究的共同主要终点是睡眠开始后的醒来时间(WASO)和通过笔法测量的睡眠潜伏期(SL)。还评估了其他继发性睡眠和疼痛终点。结果:意向性治疗人群分别包括研究一和研究二的712和267个受试者。在第一个研究中,仅NS 440 mg / DPH 50 mg组合显示出WASO与单独使用NS(-70.3分钟,p = 0.0002)和SL与单独使用DPH(分别为25.50和41.50分钟,p <0.0001)的显着改善。 。在第二项研究中,与单独使用任一成分相比,NS 440 mg / DPH 25 mg的组合未能显示出任何明显的改善。结论:仅NS 440 mg / DPH 50 mg组合显示睡眠潜伏期相对于DPH 50 mg有所改善,睡眠维持(WASO)与NS 440 mg相比均有改善。两项研究均未报告严重或意外的不良事件。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号